Redondo-Rodriguez, R.Godoy-Navarrete, F.Morales-Garrido, P.Rojas-Gimenez, M.Romero-Barco, C. M.Mena-Vazquez, N.2023-05-032023-05-032022-06-01Rodriguez RR, Godoy-Navarrete F, Morales-Garrido P, Rojas-Giménez M, Romero-Barco CM, Mena-Vázquez N. POS0654 EFFECTIVENESS OF ABATACEPT IN PATIENTS WITH INTERSTITIAL LUNG DISEASE ASSOCIATED WITH RHEUMATOID ARTHRITIS. Annals Of The Rheumatic Diseases [Internet]. 23 de mayo de 2022;81(Suppl 1):599.1-5990003-4967http://hdl.handle.net/10668/20095Background: Interstitial Lung Disease (ILD) is the most common lung involvement in rheumatoid arthritis (RA) and leads to increased morbidity and mortality. Some retrospective observational studies suggest that abatacept (ABT) could be effective and safety, although there are no clinical trials and prospectively collected data are scarce. Objectives: To evaluate prospective the effectiveness and safety of ABT in patients with ILD associated RA (ILD-RA).enAbataceptRetrospective studiesProspective studiesHumansArthritis, rheumatoidLung diseases, interstitialMorbidityLungconference outputRestricted AccessArtritis reumatoideEnfermedades pulmonares intersticialesHumanosMorbilidadPulmón10.1136/annrheumdis-2022-eular.31661468-2060https://ard.bmj.com/content/annrheumdis/81/Suppl_1/599.1.full.pdf850279002187